The story of Sildenafil offers a complicated case study for analysts eyeing drug companies. While initial sales were astounding, recent patent expiration and the arrival of generic versions have considerably affected https://lexiecfnq062179.smblogsites.com/41132698/the-blue-pill-and-the-pharmaceutical-industry-a-risky-bet